BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25833963)

  • 21. Differential expression of IFN regulatory factor 4 gene in human monocyte-derived dendritic cells and macrophages.
    Lehtonen A; Veckman V; Nikula T; Lahesmaa R; Kinnunen L; Matikainen S; Julkunen I
    J Immunol; 2005 Nov; 175(10):6570-9. PubMed ID: 16272311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brentuximab vedotin in the treatment of CD30+ PTCL.
    Barta SK; Gong JZ; Porcu P
    Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of IRF4 in IFN-stimulated gene induction and maintenance of Kaposi sarcoma-associated herpesvirus latency in primary effusion lymphoma cells.
    Forero A; Moore PS; Sarkar SN
    J Immunol; 2013 Aug; 191(3):1476-85. PubMed ID: 23804715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas.
    Karube K; Kakimoto Y; Tonozuka Y; Ohshima K
    Expert Rev Hematol; 2021 Aug; 14(8):777-787. PubMed ID: 34263699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
    Agnarelli A; Mitchell S; Caalim G; Wood CD; Milton-Harris L; Chevassut T; West MJ; Mancini EJ
    Hematol Oncol; 2022 Aug; 40(3):417-429. PubMed ID: 35544413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation.
    Piccaluga PP; Agostinelli C; Califano A; Carbone A; Fantoni L; Ferrari S; Gazzola A; Gloghini A; Righi S; Rossi M; Tagliafico E; Zinzani PL; Zupo S; Baccarani M; Pileri SA
    Cancer Res; 2007 Nov; 67(22):10703-10. PubMed ID: 18006812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas.
    Mathas S; Jöhrens K; Joos S; Lietz A; Hummel F; Janz M; Jundt F; Anagnostopoulos I; Bommert K; Lichter P; Stein H; Scheidereit C; Dörken B
    Blood; 2005 Dec; 106(13):4287-93. PubMed ID: 16123212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternative NF-κB signaling promotes colorectal tumorigenesis through transcriptionally upregulating Bcl-3.
    Tao Y; Liu Z; Hou Y; Wang S; Liu S; Jiang Y; Tan D; Ge Q; Li C; Hu Y; Liu Z; Chen X; Wang Q; Wang M; Zhang X
    Oncogene; 2018 Nov; 37(44):5887-5900. PubMed ID: 29973688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells.
    Guo F; Sun A; Wang W; He J; Hou J; Zhou P; Chen Z
    Mol Immunol; 2009 Aug; 46(13):2441-8. PubMed ID: 19540595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.
    Boddicker RL; Razidlo GL; Dasari S; Zeng Y; Hu G; Knudson RA; Greipp PT; Davila JI; Johnson SH; Porcher JC; Smadbeck JB; Eckloff BW; Billadeau DD; Kurtin PJ; McNiven MA; Link BK; Ansell SM; Cerhan JR; Asmann YW; Vasmatzis G; Feldman AL
    Blood; 2016 Sep; 128(9):1234-45. PubMed ID: 27297792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells.
    Odqvist L; Sánchez-Beato M; Montes-Moreno S; Martín-Sánchez E; Pajares R; Sánchez-Verde L; Ortiz-Romero PL; Rodriguez J; Rodríguez-Pinilla SM; Iniesta-Martínez F; Solera-Arroyo JC; Ramos-Asensio R; Flores T; Palanca JM; Bragado FG; Franjo PD; Piris MA
    Clin Cancer Res; 2013 May; 19(9):2319-30. PubMed ID: 23536439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.
    Wada DA; Law ME; Hsi ED; Dicaudo DJ; Ma L; Lim MS; Souza Ad; Comfere NI; Weenig RH; Macon WR; Erickson LA; Ozsan N; Ansell SM; Dogan A; Feldman AL
    Mod Pathol; 2011 Apr; 24(4):596-605. PubMed ID: 21169992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
    Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
    Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.
    Han SS; Yun H; Son DJ; Tompkins VS; Peng L; Chung ST; Kim JS; Park ES; Janz S
    Mol Cancer; 2010 Apr; 9():97. PubMed ID: 20433747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.
    de Leval L; Rickman DS; Thielen C; Reynies Ad; Huang YL; Delsol G; Lamant L; Leroy K; Brière J; Molina T; Berger F; Gisselbrecht C; Xerri L; Gaulard P
    Blood; 2007 Jun; 109(11):4952-63. PubMed ID: 17284527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics.
    Moroch J; Copie-Bergman C; de Leval L; Plonquet A; Martin-Garcia N; Delfau-Larue MH; Molinier-Frenkel V; Belhadj K; Haioun C; Audouin J; Swerdlow SH; Marafioti T; Gaulard P
    Am J Surg Pathol; 2012 Nov; 36(11):1636-46. PubMed ID: 23073322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
    Xie Z; Bi C; Chooi JY; Chan ZL; Mustafa N; Chng WJ
    Leukemia; 2015 Dec; 29(12):2347-54. PubMed ID: 26196464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.
    Kawamoto K; Miyoshi H; Suzuki T; Sasaki Y; Yamada K; Yanagida E; Muto R; Kiryu M; Sone H; Seto M; Ohshima K; Takizawa J
    Hematol Oncol; 2018 Feb; 36(1):166-173. PubMed ID: 29052238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High intratumoural galectin-1 expression predicts adverse outcome in ALK
    Holst JM; Ludvigsen M; Hamilton-Dutoit SJ; Bendix K; Plesner TL; Nørgaard P; Møller MB; Steiniche T; Rabinovich GA; d'Amore F; Pedersen MB
    Hematol Oncol; 2020 Feb; 38(1):59-66. PubMed ID: 31834627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells.
    Sperling S; Fiedler P; Lechner M; Pollithy A; Ehrenberg S; Schiefer AI; Kenner L; Feuchtinger A; Kühn R; Swinerd G; Schmidt-Supprian M; Strobl LJ; Zimber-Strobl U
    Blood; 2019 Jun; 133(24):2597-2609. PubMed ID: 30962205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.